Abstract
We describe a case with prolonged survival of 2 years in a female patient with pancreatic ductal adenocarcinoma who, at diagnosis, already had liver spread and eventually succumbed to brain metastases which scanned positive with [(111)In-DTPA] octreotide scintiscan (OctreoScan). Subsequently, the patient underwent a craniotomy for resection of the metastases, but her condition deteriorated. A chromogranin A stain was negative, showing that there was no neuroendocrinal component to the cerebral secondaries. In contrast, tumor labeling with a monoclonal antibody associated with a favorable prognosis in pancreatic neoplasms was positive. There is mounting evidence that somatostatin receptor status confers a relatively favorable prognosis in pancreatic adenocarcinoma, although OctreoScan-positive brain metastases have not been previously reported.
This is a preview of subscription content, log in via an institution to check access.
References
Kuratsu J, Murakami M, Uemura S, Ushio Y. Brain and skull metastases of hepatic or pancreatic cancer—report of six cases. Neurol Med Chir (Tokyo). 1990;30:476–482.
Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol. 1998;10:362–366.
Tobi M, Hatfield J, Adsay V, et al. Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms. Int J Pancreatol. 2001;29:139–148.
Yamada K, Miura M, Miyayama H, Sakashita N, Kochi M, Ushio Y. Brain metastases from asymptomatic adenocarcinoma of the pancreas: an autopsy case report. Surg Neurol. 2002;58:332–336.
Tobi M, Hatfield J, Adsay V, et al. Adnab-9 monoclonal antibody may identify long term pancreatic survivors. Proceedings of the American Association for Cancer Research (AACR). 1998;39:228 (meeting abstract).
Fisher WE, Wu Y, Amaya F, Berger DH. Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J Surg Res. 2002;105:58–64.
Raderer M, Hamilton G, Kurtaran A, et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer. 1999;79:535–537.
Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion. 2000;62:27–32.
Fueger BJ, Hamilton G, Raderer M, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med. 2001;42:1856–1862.
Pilichowska M, Kimura N, Schindler M, Kobari M. Somatostatin type 2A receptor immunoreactivity in human pancreatic adenocarcinomas. Endocr Pathol. 2001;12:147–155.
Rochaix P, Delesque N, Estève JP, et al. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther. 1999;10:995–1008.
Celinski SA, Fisher WE, Amaya F, et al. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J Surg Res. 2003;115:41–47.
Author information
Authors and Affiliations
Corresponding author
Additional information
This manuscript is dedicated to the memory of Linda M. Albright.
Rights and permissions
About this article
Cite this article
MarepaIly, R., Micheals, D., Sloan, A. et al. Octreotide Uptake in Intracranial Metastasis of Pancreatic Ductal Adenocarcinoma Origin in a Patient with a Prolonged Clinical Course. Dig Dis Sci 54, 188–190 (2009). https://doi.org/10.1007/s10620-008-0531-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0531-4